Research Grants

Funding For:

How Does Interchangeability Impact Biosimilar Adoption?

Prescription Drugs


Recipient:

Pragya Kakani, Weill Cornell Medicine & Luca Maini, Harvard Medical School

Grant Period:

Jan 01, 2024 - Dec 31, 2024

AMOUNT:

$27,888.00

Summary of the Project:

Biosimilar adoption could reduce health care spending and improve medication affordability. One barrier to adoption is that pharmacists are not permitted to substitute biosimilars for original biologics unless the biosimilar is deemed “interchangeable” by the Food and Drug Administration. This study will evaluate how interchangeability affects biosimilar adoption, whether the effects are different for new versus existing patients, and the role played by state substitution policies in mediating these effects. The study may offer valuable insights to policymakers assessing substitution laws.